Dedicated to discovering, developing, and commercializing novel therapeutics to transform the treatment of patients with grievous blood-based disorders


GBT (NASDAQ: GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT’s lead product candidate is voxelotor (formerly known as GBT440), an oral, once-daily therapy that modulates hemoglobin’s affinity for oxygen, which the company believes inhibits hemoglobin polymerization in sickle cell disease.


Year Invested: 2012
Location: South San Francisco, Calif.
Visit: www.gbt.com/

Recent News

January 9, 2018
GBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD)

January 3, 2018
GBT to Present at the 36th Annual J.P. Morgan Healthcare Conference

December 22, 2017
GBT Appoints Wendy L. Yarno to Board of Directors

Read More News

Associated Team Members

Kevin Starr
Partner

Mark A. Goldsmith, M.D., Ph.D.
Venture Partner

Craig Muir
Partner/Chief Technology Officer

Charles Homcy, M.D.
Partner

Glenn Pierce, M.D., Ph.D.
Entrepreneur-in-Residence